Paige Achieves CE Mark in Breast Cancer Detection and Prostate Cancer Risk Quantification and Classification Using Digital AI-Based Diagnostics
Wednesday, December 09, 2020
Paige , a global leader in AI-based digital diagnostics,announced that it has been CE marked for Paige Breast, its breast cancer detection software that tells pathologists who breast biopsies assess suspicious areas for further investigation. The company has also been CE marked for Paige Prostate Grading & Quantification, a digital diagnostic that uses slide level information for primary and secondary Gleason models and tumor size to best facilitate the treatment to be planned. . Thanks to these CE marks, both products are now available in laboratories and hospitals in the European Economic Area, Switzerland and the United Kingdom.
“The CE mark for breast cancer is an important regulatory approval for our computational pathology products as we expand our applications in oncology, while the CE mark for prostate cancer strengthens the characteristics of risk classification and quantification of our already CE marked Paige Prostate offering, ”said Leo Grady, Ph.D., CEO of Paige. “We continue to rapidly advance new products that improve the pathology process and build confidence in the diagnosis for some of the most common cancers, including breast cancer. Thank you very much to all of the Paige team and to our fellow physicians around the world who have helped advance this technology in order to optimize patient outcomes. "
Paige Breast Leads the Way to Predictions of Breast Cancer Presence at Slide and Case Level
For pathologists responsible for diagnosing breast cancer - the cancer most commonly diagnosed in women in European countries 1 - the potentially large volume of slides of breast tissue to be examined can pose problems in workload management and productivity of pathologists. Paige Breast was designed to educate pathologists on the characteristics of breast tissue laminae and enable them to predict the presence of lamina and case cancer. This feature helps pathologists more easily, efficiently and safely identify small foci of cancer that may easily go unnoticed.
"By reducing the gaps between observers, uncertainty and time, this technology will enable pathologists to deliver more efficient treatment, which will allow patients to receive the best care," said Dr Matthew Hanna, Director of pathology computer science at Memorial Sloan Kettering Cancer Center. “These technologies have the potential to increase physician productivity while minimizing burnout, especially for high-incidence diseases, such as breast cancer, where hospitals may be faced with a high volume of patient cases. "
Paige is continuously improving the functionality of Paige Breast, including risk quantification and subtyping, for future deployment.
Streamlining Prostate Cancer Diagnosis Through AI-Based Classification and Risk Quantification
Classification and quantification of prostate tissue is a time consuming and often subjective task, leading to large disparities between observers in the diagnostic process. Paige Prostate can boost the pathologist's confidence in the diagnosis, while improving consistency and standardization, with the addition of new risk ranking and quantification features.
Paige Prostate Grading & Quantification provides slide-level information on primary and secondary Gleason patterns, tumor length and proportion. The product provides visual overlays that indicate specific regions of the slide corresponding to each Gleason pattern, which can reduce the time it takes for a pathologist to determine and measure a grade. What's more, Paige Prostate Grading & Quantification is characterized by high concordance with subspecialty pathologists, meaning that the technology can reduce the need for a pathologist to report cases for further examination without compromising diagnostic accuracy. . This technology thus streamlines workflows in order to reduce lead times.
For more information on Paige Breast, Paige Prostate Grading & Quantification and our other solutions, please contact info@paige.ai .
About Paige
Paige was founded in 2017 by Thomas Fuchs, dr sc. and colleagues at Memorial Sloan Kettering Cancer Center (MSKCC). The company manufactures computational pathology products, designed so that patients and healthcare teams can make better informed and more effective treatment decisions. With this new class of AI technologies positioned to drive the growth of diagnostics, Paige has created a platform that puts this innovative technology at the service of pathologists, transforming their workflows and boosting diagnostic reliability and productivity. Paige's products provide information to pathologists and oncologists, which helps them efficiently reach more accurate diagnoses for the benefit of their patients.
To learn more, please visit: https://www.Paige.ai , https://www.paigeplatform.com , Twitter and LinkedIn .
Dr. Matthew Hanna is a paid consultant to Paige. MSK has intellectual property rights and associated financial interests related to Paige under license agreements between MSK and Paige.
1 The Cancer Atlas - The Burden: Europe. American Cancer Society. Last consulted: November 23, 2020. https://canceratlas.cancer.org/wp-content/uploads/2019/09/CA3_Europe.pdf
The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared to the source text, which will set a precedent.
Contacts
Jon Yu
Westwicke / ICR Healthcare PR
Tel. : 475.395.5375
Jon.Yu@westwicke.com